PINC vs. INDV, JANX, QDEL, SMMT, CGON, RYTM, HIMS, MRUS, CORT, and ICUI
Should you be buying Premier stock or one of its competitors? The main competitors of Premier include Indivior (INDV), Janux Therapeutics (JANX), QuidelOrtho (QDEL), Summit Therapeutics (SMMT), CG Oncology (CGON), Rhythm Pharmaceuticals (RYTM), Hims & Hers Health (HIMS), Merus (MRUS), Corcept Therapeutics (CORT), and ICU Medical (ICUI). These companies are all part of the "medical" sector.
Premier (NASDAQ:PINC) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
In the previous week, Indivior had 3 more articles in the media than Premier. MarketBeat recorded 11 mentions for Indivior and 8 mentions for Premier. Premier's average media sentiment score of 0.29 beat Indivior's score of -0.28 indicating that Premier is being referred to more favorably in the media.
Premier received 609 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 69.35% of users gave Premier an outperform vote.
Premier has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
Premier has higher revenue and earnings than Indivior. Premier is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
74.4% of Premier shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 0.9% of Premier shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Premier has a net margin of 12.71% compared to Indivior's net margin of 0.44%. Indivior's return on equity of 842.72% beat Premier's return on equity.
Premier presently has a consensus price target of $25.15, suggesting a potential upside of 20.45%. Indivior has a consensus price target of $36.00, suggesting a potential upside of 105.01%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Premier.
Summary
Indivior beats Premier on 9 of the 17 factors compared between the two stocks.
Get Premier News Delivered to You Automatically
Sign up to receive the latest news and ratings for PINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
